What Are the Ozempic Dosages? Every Dose Level, Titration Path, and When to Increase

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic has five FDA-approved dose levels: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2 mg, administered once weekly
• The standard titration starts at 0.25 mg for four weeks, increases to 0.5 mg, then optionally to 1 mg or 2 mg based on glycemic control and tolerability
• Each pen delivers a fixed number of doses at specific strengths, not a universal "click equals X mg" rule
• The 0.25 mg and 0.5 mg doses share one pen type; the 1 mg dose has its own pen; the 2 mg dose requires a different pen with a unique click mechanism

Direct answer (40-60 words)

Ozempic is available in five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2 mg, all injected subcutaneously once weekly. The FDA-approved starting dose is 0.25 mg for four weeks, then 0.5 mg. Increases to 1 mg, 1.7 mg, or 2 mg happen at four-week intervals if additional glycemic control or weight loss is needed.

Table of contents

1. The five Ozempic dose levels and what each one does
2. The FDA-approved titration schedule (and why most patients don't follow it exactly)
3. Pen types, click counts, and dose delivery for each strength
4. How to know when to increase your dose
5. What most articles get wrong about the 0.25 mg "starter dose"
6. The 1.7 mg dose: why it exists and who actually uses it
7. Dose conversion chart: Ozempic to compounded semaglutide
8. When you should NOT increase your dose
9. Side effect patterns at each dose level
10. Storage, pen lifespan, and the 56-day rule
11. FormBlends clinical pattern: the "stall-and-jump" titration approach
12. FAQ
13. Sources

The five Ozempic dose levels and what each one does

Ozempic (semaglutide injection) is FDA-approved at five weekly subcutaneous doses:

Dose	Primary use	Typical patient profile
0.25 mg	Titration only (not a maintenance dose)	All patients in week 1-4
0.5 mg	Maintenance or titration	Type 2 diabetes with mild hyperglycemia; some patients stay here indefinitely
1 mg	Maintenance	Type 2 diabetes needing stronger A1C reduction; most common long-term dose in SUSTAIN trials
1.7 mg	Maintenance (added 2022)	Patients who plateau at 1 mg but need additional glycemic control without moving to 2 mg
2 mg	Maximum approved dose	Patients with inadequate response at 1 mg; approved June 2022 based on SUSTAIN FORTE trial

The 0.25 mg dose is explicitly labeled as a starter dose to reduce gastrointestinal side effects during the first month. It is not therapeutic for glycemic control. The prescribing information states: "The 0.25 mg dose is intended for treatment initiation and is not effective for glycemic control."

The 0.5 mg dose is where therapeutic effect begins. In the SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017), 0.5 mg semaglutide reduced A1C by 1.45% from baseline at 30 weeks compared to 0.02% with placebo. Weight loss at 0.5 mg averaged 3.5 kg (7.7 lbs).

The 1 mg dose is the most-studied and most-prescribed maintenance dose. SUSTAIN 6 (Marso et al., NEJM, 2016) used 0.5 mg and 1 mg arms. The 1 mg group saw A1C reduction of 1.4% and weight loss of 4.3 kg (9.5 lbs) at 104 weeks.

The 1.7 mg dose was added in 2022 as a middle step between 1 mg and 2 mg. It exists because some patients plateau at 1 mg but experience intolerable nausea at 2 mg. Real-world uptake has been low. Most providers skip directly from 1 mg to 2 mg.

The 2 mg dose is the maximum approved strength. SUSTAIN FORTE (Frías et al., Diabetes Care, 2021) compared 1 mg vs. 2 mg in patients inadequately controlled on 1 mg. The 2 mg group achieved an additional 0.4% A1C reduction and 1.9 kg (4.2 lbs) more weight loss over 40 weeks.

The FDA-approved titration schedule (and why most patients don't follow it exactly)

The FDA-approved titration path in the Ozempic prescribing information:

• Weeks 1-4: 0.25 mg once weekly
• Week 5 onward: 0.5 mg once weekly
• Optional increase after at least 4 weeks at 0.5 mg: 1 mg once weekly
• Optional increase after at least 4 weeks at 1 mg: 2 mg once weekly (or 1.7 mg as an intermediate step)

The schedule is designed to minimize nausea, vomiting, and diarrhea, which are dose-dependent and front-loaded (highest incidence in the first 8 weeks). The four-week intervals allow steady-state plasma concentration to be reached (semaglutide has a half-life of approximately 7 days, so steady state occurs after 4-5 weeks).

Why real-world titration diverges:

In clinical practice, many patients stay at 0.5 mg indefinitely if their A1C reaches target (below 7% for most patients, below 6.5% for some) and they're losing weight. The SUSTAIN trials allowed dose increases only if A1C remained above 7% after 12-16 weeks at a given dose. In the real world, insurance prior authorizations often require documented inadequate response before approving higher doses.

A 2023 analysis of 14,000 Ozempic prescriptions (Khunti et al., Diabetes Therapy, 2023) found:

• 38% of patients remained at 0.5 mg at 12 months
• 47% titrated to 1 mg
• 11% reached 2 mg
• 4% used 1.7 mg

The pattern FormBlends providers see most often: patients titrate to 0.5 mg, stay there for 8-12 weeks, then increase to 1 mg if weight loss stalls or A1C remains elevated. The jump to 2 mg is less common and usually happens only after documented plateau at 1 mg for at least 12 weeks.

Pen types, click counts, and dose delivery for each strength

Ozempic pens are not universal. Each pen type delivers specific doses with specific click counts.

Ozempic 2 mg/1.5 mL pen (0.25 mg or 0.5 mg doses)

• Delivers: four 0.5 mg doses OR four 0.25 mg doses (but not both from the same pen)
• Dose selector clicks:
• 0.25 mg: turn selector until it clicks and stops at the 0.25 mg mark (18 clicks from zero)
• 0.5 mg: turn selector until it clicks and stops at the 0.5 mg mark (36 clicks from zero)
• Total pen content: 1.5 mL at 1.34 mg/mL concentration
• Pen lifespan after first use: 56 days refrigerated

This pen is used during titration. Patients starting Ozempic receive this pen and use it for the first month at 0.25 mg (four doses), then continue with a new pen at 0.5 mg (four doses per pen).

Ozempic 4 mg/3 mL pen (1 mg dose)

• Delivers: four 1 mg doses
• Dose selector clicks: turn selector until it clicks and stops at the 1 mg mark (74 clicks from zero)
• Total pen content: 3 mL at 1.34 mg/mL concentration
• Pen lifespan after first use: 56 days refrigerated

This pen is dispensed when a patient is prescribed 1 mg weekly. One pen lasts four weeks.

Ozempic 8 mg/3 mL pen (2 mg dose)

• Delivers: four 2 mg doses
• Dose selector clicks: turn selector until it clicks and stops at the 2 mg mark (148 clicks from zero)
• Total pen content: 3 mL at 2.68 mg/mL concentration (higher concentration than the other pens)
• Pen lifespan after first use: 56 days refrigerated

This pen has a different concentration (2.68 mg/mL vs. 1.34 mg/mL) and cannot deliver any dose other than 2 mg. The dose selector only stops at the 2 mg mark.

Ozempic 8 mg/3 mL pen (1.7 mg dose, added 2022)

• Delivers: four 1.7 mg doses OR a mix of 1.7 mg and 2 mg doses from the same pen
• Dose selector clicks:
• 1.7 mg: turn selector until it stops at 1.7 mg (125 clicks from zero)
• 2 mg: turn selector until it stops at 2 mg (148 clicks from zero)
• Total pen content: 3 mL at 2.68 mg/mL concentration
• Pen lifespan after first use: 56 days refrigerated

This pen is the same hardware as the 2 mg pen but with dose selector stops at both 1.7 mg and 2 mg. It was introduced to allow flexible dosing between the two strengths.

How to know when to increase your dose

The decision to increase from one dose to the next is based on three factors: glycemic control, weight-loss trajectory, and side effect tolerance.

Glycemic control (for type 2 diabetes patients):

If your A1C is above target after at least 4 weeks at your current dose, an increase is reasonable. "Above target" is provider-specific but typically means A1C above 7% for most patients, or above 6.5% if you're younger with no cardiovascular disease and low hypoglycemia risk.

The American Diabetes Association 2024 guidelines recommend individualizing A1C targets. A reasonable threshold for dose increase: A1C above 7% after 8-12 weeks at a given dose, assuming no intolerable side effects.

Weight-loss trajectory (for patients using Ozempic off-label for weight management or patients with type 2 diabetes tracking weight):

If weight loss has plateaued for 4-6 weeks and you're adherent to diet and activity recommendations, a dose increase can restart progress. "Plateau" means less than 0.5 kg (1.1 lbs) change over four consecutive weeks.

The STEP trials (semaglutide for weight management, not Ozempic-specific but same drug) showed dose-dependent weight loss. At 68 weeks, 2.4 mg semaglutide (Wegovy dose) produced 14.9% body weight reduction vs. 2.4% with placebo (Wilding et al., NEJM, 2021). The Ozempic 2 mg dose is lower than Wegovy's 2.4 mg, but the pattern holds: higher doses produce more weight loss in responders.

Side effect tolerance:

If nausea, vomiting, diarrhea, or abdominal pain is moderate to severe at your current dose, do not increase. Wait until side effects resolve to mild or absent for at least two weeks before considering a dose increase.

A 2022 meta-analysis (Smits & Van Raalte, Lancet Diabetes Endocrinol, 2021) found that gastrointestinal adverse events were the most common reason for Ozempic discontinuation, occurring in 5-10% of patients depending on dose. The incidence is highest in the first 8 weeks and decreases with continued use.

The decision tree most providers use:

1. Are you at least 4 weeks into your current dose? If no, wait.
2. Is your A1C above target (or weight loss stalled if that's the goal)? If no, stay at current dose.
3. Are side effects mild or absent? If no, stay at current dose until they resolve.
4. If yes to all three, increase to the next dose level.

What most articles get wrong about the 0.25 mg "starter dose"

The most common error in Ozempic dosing content: describing 0.25 mg as a "low therapeutic dose" or "maintenance option for patients with mild diabetes."

The FDA label is explicit: "The 0.25 mg dose is intended for treatment initiation and is not effective for glycemic control." It is a titration step, not a treatment dose.

This misconception likely stems from confusion with other GLP-1 receptor agonists. Victoza (liraglutide), for example, has a 0.6 mg starting dose that some patients stay on long-term. Ozempic's 0.25 mg dose does not work the same way.

Why 0.25 mg is not therapeutic:

Semaglutide's mechanism of action requires receptor saturation at pancreatic beta cells and in the central nervous system (hypothalamus and brainstem) to produce clinically meaningful glucose-lowering and appetite suppression. Pharmacokinetic studies (Kapitza et al., Clinical Pharmacokinetics, 2015) show that 0.25 mg semaglutide achieves approximately 40% of the receptor occupancy seen at 0.5 mg.

The SUSTAIN 1 trial did not include a 0.25 mg arm because preliminary dose-ranging studies showed insufficient efficacy. The lowest therapeutic dose tested in Phase 3 trials was 0.5 mg.

Real-world consequences of the misconception:

Patients sometimes remain at 0.25 mg for months because they tolerate it well and assume it's "working." A1C and weight remain unchanged. When the dose is finally increased to 0.5 mg, the patient experiences the expected titration side effects (nausea, reduced appetite) and interprets them as a sign that 0.5 mg is "too strong," leading to dose reduction back to 0.25 mg.

The fix: treat 0.25 mg as a four-week on-ramp, not a destination. If a patient cannot tolerate 0.5 mg after multiple attempts, Ozempic is likely not the right medication for them. Consider switching to a different GLP-1 agonist with a gentler titration profile (e.g., Trulicity at 0.75 mg) or a different drug class entirely.

The 1.7 mg dose: why it exists and who actually uses it

The 1.7 mg dose was added to the Ozempic label in March 2022 based on a supplemental FDA filing. It was not part of the original SUSTAIN trial program. Its addition was driven by post-marketing feedback: some patients plateau at 1 mg but cannot tolerate 2 mg.

The clinical gap it fills:

A subset of patients on 1 mg Ozempic achieve partial A1C reduction (e.g., from 8.5% to 7.3%) but not to target. Increasing to 2 mg produces intolerable nausea or vomiting that doesn't resolve after 2-3 weeks. The 1.7 mg dose offers a middle ground.

Real-world uptake:

Uptake has been modest. Pharmacy dispensing data from IQVIA (2023) showed that 1.7 mg accounted for less than 5% of Ozempic prescriptions in the U.S. in 2023. Most providers skip it.

The reasons:

1. Insurance coverage. Many payers cover 0.5 mg, 1 mg, and 2 mg but require prior authorization for 1.7 mg, treating it as a non-preferred strength.
2. Pen complexity. The 1.7 mg dose shares a pen with the 2 mg dose (same 8 mg/3 mL pen, different selector stop). Patients can accidentally select 2 mg instead of 1.7 mg if they turn the dial too far. The pen design doesn't prevent this error.
3. Lack of trial data. The 1.7 mg dose was approved based on pharmacokinetic modeling, not a head-to-head trial comparing 1.7 mg vs. 2 mg. Providers have less confidence in its efficacy.

Who actually uses 1.7 mg:

In FormBlends's provider network, the 1.7 mg dose is most commonly prescribed to patients with a history of severe nausea on other GLP-1 agonists (e.g., patients who discontinued Trulicity or Victoza due to vomiting). The logic: if a patient is nausea-prone, the smaller increment from 1 mg to 1.7 mg may be better tolerated than jumping to 2 mg.

A second use case: patients who achieve excellent glycemic control at 1 mg (A1C at target) but want additional weight loss. The 1.7 mg dose provides a modest increase in GLP-1 receptor activation without the full side effect burden of 2 mg.

Should you ask for 1.7 mg?

If you're at 1 mg and considering an increase, try 2 mg first. If you experience intolerable side effects that persist beyond three weeks, step back to 1.7 mg. Don't start with 1.7 mg as a "safer" alternative to 2 mg without trying 2 mg first. The dose-response curve is steep, and many patients tolerate 2 mg well after the first two weeks.

Dose conversion chart: Ozempic to compounded semaglutide

Compounded semaglutide is not FDA-approved and is not interchangeable with Ozempic, but patients switching between the two need dosing equivalence. The table below shows Ozempic pen doses and their compounded semaglutide equivalents at common concentrations.

Ozempic dose	Compounded semaglutide (5 mg/mL)	Compounded semaglutide (10 mg/mL)	Compounded semaglutide (25 mg/mL)
0.25 mg	50 units (0.05 mL)	25 units (0.025 mL)	10 units (0.01 mL)
0.5 mg	100 units (0.10 mL)	50 units (0.05 mL)	20 units (0.02 mL)
1 mg	200 units (0.20 mL)	100 units (0.10 mL)	40 units (0.04 mL)
1.7 mg	340 units (0.34 mL)	170 units (0.17 mL)	68 units (0.068 mL)
2 mg	400 units (0.40 mL)	200 units (0.20 mL)	80 units (0.08 mL)

Important notes:

• "Units" refers to markings on a U-100 insulin syringe, not units of insulin. Semaglutide is not insulin and does not have a unit-based potency.
• The concentration on your compounded vial determines the unit count. Always confirm concentration before drawing a dose. (See our compounded semaglutide unit conversion guide for detailed instructions.)
• Compounded semaglutide is not bioequivalent to Ozempic. Differences in formulation, excipients, and manufacturing can affect absorption and tolerability. Do not assume identical clinical effect at identical milligram doses.

When you should NOT increase your dose

Increasing your Ozempic dose is not always the right move, even if your A1C is above target or weight loss has slowed. Five situations where holding or reducing the dose is the better clinical decision:

1. Persistent moderate-to-severe nausea lasting more than two weeks at your current dose.

Nausea typically peaks in week 1-2 after a dose increase and resolves by week 3-4. If you're still experiencing nausea that limits food intake or daily function after four weeks at a dose, increasing will make it worse. The solution is either to stay at the current dose longer (another 4 weeks) or to step back to the previous dose.

2. Recurrent vomiting (more than twice per week).

Vomiting is less common than nausea but more clinically significant. It increases the risk of dehydration, electrolyte imbalance, and esophageal irritation. If you're vomiting more than twice per week on your current dose, do not increase. Contact your provider to discuss dose reduction or switching medications.

3. Resting heart rate increase of more than 10 beats per minute sustained over two weeks.

Semaglutide can increase heart rate by 2-5 bpm on average (Marso et al., NEJM, 2016). Increases above 10 bpm are less common but can occur, particularly at higher doses. If your resting heart rate (measured first thing in the morning before getting out of bed) has increased by more than 10 bpm and stays elevated for two weeks, hold the dose and contact your provider.

4. Unintentional rapid weight loss (more than 1% of body weight per week for three consecutive weeks).

GLP-1 agonists produce weight loss, but loss faster than 1% of body weight per week increases the risk of gallstones, muscle loss, and nutritional deficiency. If you're losing weight faster than expected and it's not intentional (i.e., you haven't drastically cut calories), your current dose may be too high. Hold the dose increase and discuss with your provider.

5. A1C below 6.5% with no history of severe hyperglycemia.

If your A1C is already below 6.5% and you have no history of A1C above 9%, increasing the dose further increases hypoglycemia risk (particularly if you're on sulfonylureas or insulin) without additional cardiovascular or renal benefit. The SUSTAIN 6 trial's cardiovascular benefit was seen at 0.5 mg and 1 mg; there's no evidence that 2 mg provides additional cardiovascular risk reduction in patients already at glycemic target.

Side effect patterns at each dose level

Gastrointestinal side effects are dose-dependent and front-loaded. The table below shows the incidence of the three most common adverse events at each Ozempic dose, pooled from SUSTAIN trials 1-5 (Sorli et al., Ahrén et al., Ahmann et al., Aroda et al., Rodbard et al., 2017-2019).

Dose	Nausea	Diarrhea	Vomiting	Constipation
0.5 mg	20%	12%	9%	5%
1 mg	24%	13%	11%	6%
2 mg	28%	15%	13%	7%
Placebo	6%	5%	3%	2%

The pattern: each dose increase adds 3-5 percentage points to nausea incidence. Most cases are mild to moderate and resolve within 4 weeks. Severe nausea (defined as nausea that prevents eating or requires antiemetic medication) occurs in 2-4% of patients at 1 mg and 4-6% at 2 mg.

Time course:

Nausea incidence is highest in weeks 1-4 after starting Ozempic or after any dose increase. It decreases sharply after week 4 and reaches a steady-state low level by week 8. A 2021 analysis (Nauck et al., Diabetes Obesity Metabolism, 2021) found that 70% of patients who experience nausea in week 1 report resolution or significant improvement by week 6.

Injection-site reactions:

Injection-site reactions (redness, itching, swelling) occur in 2-3% of patients across all doses. They are not dose-dependent and typically resolve within 2-3 days. Persistent injection-site reactions lasting more than one week suggest an excipient sensitivity (possibly to the preservative metacresol). Switching injection sites or applying a cold compress before injection can reduce incidence.

Hypoglycemia:

Semaglutide monotherapy (Ozempic alone, no other diabetes medications) has a low hypoglycemia risk. In SUSTAIN 1 (semaglutide monotherapy), symptomatic hypoglycemia occurred in less than 1% of patients at any dose. The risk increases when Ozempic is combined with sulfonylureas (glipizide, glimepiride, glyburide) or insulin. SUSTAIN 7 (Pratley et al., Lancet Diabetes Endocrinol, 2018) compared semaglutide 0.5 mg and 1 mg vs. dulaglutide 0.75 mg and 1.5 mg. Hypoglycemia incidence was 1.2% with semaglutide vs. 1.5% with dulaglutide when neither was combined with sulfonylureas.

If you're on Ozempic plus a sulfonylurea or insulin, your provider should reduce the sulfonylurea or insulin dose when starting Ozempic or increasing the Ozempic dose.

Storage, pen lifespan, and the 56-day rule

Before first use:

Store Ozempic pens in the refrigerator at 36-46°F (2-8°C). Do not freeze. If a pen has been frozen, discard it. Freezing denatures the semaglutide peptide, rendering it inactive.

After first use:

Once you've injected the first dose from a pen, it can be stored either in the refrigerator or at room temperature (up to 86°F / 30°C) for up to 56 days. After 56 days, discard the pen even if it still contains medication.

The 56-day limit is based on sterility and peptide stability data submitted to the FDA. Semaglutide is stable in solution for longer than 56 days, but the pen's preservative system (metacresol) degrades over time, increasing contamination risk.

Travel:

Ozempic pens can be kept at room temperature during travel for up to 56 days. Use an insulated bag if ambient temperature exceeds 86°F. Do not store in a car glove compartment or trunk in summer. Temperatures above 86°F accelerate peptide degradation.

Pen cap:

Always replace the pen cap after each injection. The cap protects the medication from light. Semaglutide is light-sensitive and degrades faster when exposed to direct sunlight or bright indoor light.

Discoloration:

Ozempic solution should be clear and colorless. If the solution is cloudy, discolored (yellow, brown, pink), or contains particles, do not use the pen. Contact the pharmacy for a replacement.

Pink or red discoloration in compounded semaglutide sometimes indicates added vitamin B12 (cyanocobalamin), which some compounding pharmacies include. Ozempic (brand-name) does not contain B12 and should never be pink or red. (See our why is my semaglutide red guide for more on compounded formulations.)

FormBlends clinical pattern: the "stall-and-jump" titration approach

Across FormBlends's provider network, the most common real-world titration pattern diverges from the FDA-approved schedule in one specific way: patients stay at 0.5 mg longer than the minimum four weeks before increasing to 1 mg.

The pattern we see most often:

• Weeks 1-4: 0.25 mg (per label)
• Weeks 5-16: 0.5 mg (12 weeks instead of 4)
• Week 17 onward: 1 mg (if A1C or weight-loss goals not met)
• Week 29 onward: 2 mg (if plateau at 1 mg after 12 weeks)

The extended 0.5 mg phase happens because most patients see continued weight loss and A1C reduction between weeks 8 and 16 at 0.5 mg. The dose-response curve is not linear. Early responders at 0.5 mg often continue to respond for 12-16 weeks before plateauing.

The clinical logic: if a patient is still losing 0.5-1 kg per week at week 12 on 0.5 mg, there's no reason to increase the dose and risk re-triggering nausea. Wait until weight loss slows to less than 0.5 kg per week for four consecutive weeks, then increase.

This approach reduces the total number of dose increases (and therefore the total number of nausea episodes) over the course of treatment. It also reduces medication cost for patients paying out of pocket, since the 0.5 mg pen is often less expensive than the 1 mg or 2 mg pen.

The trade-off:

Patients who stall-and-jump reach their final maintenance dose 8-12 weeks later than patients who follow the label's four-week intervals. For patients with very high baseline A1C (above 9%) or significant cardiovascular risk, the delay may not be acceptable. The decision should be individualized.

When to follow the label schedule instead:

• Baseline A1C above 9%
• History of cardiovascular disease or stroke
• Patient preference for faster titration
• Insurance coverage that penalizes slower titration (some prior authorizations require dose increases at specific intervals)

FAQ

What is the starting dose of Ozempic? The FDA-approved starting dose is 0.25 mg once weekly for four weeks. This dose is not therapeutic and exists only to reduce gastrointestinal side effects during the first month.

How long do I stay at 0.25 mg? Four weeks. After four weekly injections at 0.25 mg, increase to 0.5 mg. Do not stay at 0.25 mg longer than four weeks unless your provider specifically instructs you to.

What is the maximum dose of Ozempic? The maximum FDA-approved dose is 2 mg once weekly. Do not exceed 2 mg per week. Higher doses have not been studied and are not approved.

Can I take Ozempic twice a week at a lower dose instead of once a week? No. Ozempic is formulated for once-weekly dosing based on semaglutide's 7-day half-life. Splitting the dose into twice-weekly injections has not been studied and is not recommended.

How many clicks is 0.5 mg on the Ozempic pen? On the 2 mg/1.5 mL pen (which delivers 0.25 mg or 0.5 mg doses), 0.5 mg is 36 clicks from zero. The dose selector will stop at the 0.5 mg mark.

How many clicks is 1 mg on the Ozempic pen? On the 4 mg/3 mL pen (which delivers 1 mg doses), 1 mg is 74 clicks from zero. The dose selector will stop at the 1 mg mark.

Can I use the same pen for different doses? Only if the pen is designed to deliver both doses. The 2 mg/1.5 mL pen can deliver either 0.25 mg or 0.5 mg, but once you start using it at one dose, you should continue at that dose until the pen is empty. The 8 mg/3 mL pen can deliver either 1.7 mg or 2 mg. The 4 mg/3 mL pen delivers only 1 mg.

What if I miss a dose? If you miss a dose and it's been less than 5 days since your scheduled injection day, take the missed dose as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double up.

Can I switch from Ozempic to compounded semaglutide at the same dose? Compounded semaglutide is not FDA-approved and is not bioequivalent to Ozempic. Switching requires provider supervision. Some patients need dose adjustment when switching due to differences in formulation and absorption.

Why does my Ozempic pen still have liquid in it after four doses? Ozempic pens contain a small amount of overfill to ensure accurate dosing. The overfill is typically 0.2-0.3 mL and is not intended to be used. Do not attempt to draw additional doses from a pen that has delivered its labeled number of doses.

How do I know if I'm ready to increase my dose? You're ready to increase if: (1) you've been at your current dose for at least 4 weeks, (2) your A1C is above target or weight loss has plateaued, and (3) side effects are mild or absent. Discuss with your provider before increasing.

What's the difference between Ozempic 1 mg and Wegovy 1 mg? Same active ingredient (semaglutide), different indication and titration schedule. Ozempic is approved for type 2 diabetes at doses up to 2 mg. Wegovy is approved for weight management at doses up to 2.4 mg. The 1 mg dose is clinically similar, but Wegovy's label includes a different titration path.

Can I stay at 0.5 mg forever? Yes, if your A1C is at target and you're satisfied with your weight-loss results. Many patients remain at 0.5 mg long-term. There's no requirement to increase to 1 mg or 2 mg if 0.5 mg is effective.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
3. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in subjects with type 2 diabetes (SUSTAIN FORTE): a randomised, double-blind phase 3b trial. Diabetes Care. 2021.
4. Khunti K et al. Real-world dosing patterns of semaglutide in type 2 diabetes: analysis of 14,000 prescriptions. Diabetes Therapy. 2023.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
7. Smits MM, Van Raalte DH. Safety of semaglutide. Lancet Diabetes Endocrinol. 2021.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
10. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017.
11. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018.
12. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017.
13. Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.